AIMS:
This study aimed to assess whether enalapril could improve cardioversion outcome and facilitate sinus rhythm maintenance after conversion of chronic atrial fibrillation (AF).
METHODS AND RESULTS:
Patients with chronic AF for more than 3 months were assigned to receive either amiodarone (200mg orally 3 times a day; group I: n=75) or the same dosage of amiodarone plus enalapril (10mg twice a day; group II: n=70) 4 weeks before scheduled external cardioversion. The end-point was the time to first recurrence of AF. In 125 patients (86.2%), AF was converted to sinus rhythm. Group II had a trend to a trend to a lower rate of immediate recurrence of AF than group I did (4.3% vs 14.7%, P=0.067). Kaplan-Meier analysis demonstrated a higher probability of group II remaining in sinus rhythm at 4 weeks (84.3% vs 61.3%, P=0.002) and at the median follow-up period of 270 days (74.3% vs 57.3%, P=0.021) than in group II.
CONCLUSIONS:
The addition of enalapril to amiodarone decreased the rate of immediate and subacute arrhythmia recurrences and facilitated subsequent long-term maintenance of sinus rhythm after cardioversion of persistent AF.
Comment in
Angiotensin-converting enzyme inhibitors to maintain sinus rhythm following cardioversion of atrial fibrillation. [Curr Cardiol Rep. 2004]
A paradigm shift in treatment for atrial fibrillation: from electrical to structural therapy? [Eur Heart J. 2003]
Atrial remodeling in persistent atrial fibrillation: the potential role of aldosterone. [Eur Heart J. 2004]
